# Oral SERD

Source: https://onco.cc/terms/oral-serd/  
OnCo record `oral-serd` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An oral SERD is a pill that destroys the oestrogen receptor rather than just blocking it, replacing the monthly fulvestrant injection.

## Summary

Selective oestrogen receptor degraders taken orally: elacestrant (2023), imlunestrant (2025), camizestrant (2026), giredestrant (filed), with palazestrant and others behind. Benefit as monotherapy is confined to ESR1-mutant disease; combination with CDK4/6 or everolimus extends benefit to wild-type tumours (EMBER-3, evERA). Upfront replacement of aromatase inhibitors in unselected first-line disease failed in persevERA. Adjuvant results (lidERA) are positive.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader
- Wikipedia: https://en.wikipedia.org/wiki/Selective_estrogen_receptor_degrader

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- targets: [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/)
- drugs: [Camizestrant](https://onco.cc/drugs/camizestrant/), [Elacestrant](https://onco.cc/drugs/elacestrant/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/), [Giredestrant](https://onco.cc/drugs/giredestrant/), [Imlunestrant](https://onco.cc/drugs/imlunestrant/)
- trials: [EMBER-3](https://onco.cc/trials/ember-3/)

---
JSON: https://onco.cc/api/v1/entities/oral-serd.json